# US 2018/0264099 A1 · Live attenuated oral vaccine against shigellosis and typhoid fever

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0264099 A1
- Document ID: US20180264099A1
- Status: Published application
- Kind: A1
- Application number: 15/742,459
- Filed: 2016-07-06
- Published: 2018-09-20
- Earliest claimed: 2015-07-06
- Assignees: Protein Potential, LLC
- Applicants: Protein Potential, LLC
- Inventors: YUN WU; Dennis J. KOPECKO; B. Kim Lee SIM; Stephen L. HOFFMAN
- Web page: https://patentgrep.com/patent/US20180264099A1

## CPC

- A61K 39/0283: {Shigella}
- A61K 39/0275: {Salmonella}
- A61P 31/04: Antibacterial agents
- A61K 39/116: Polyvalent bacterial antigens
- A61K 2039/522: {avirulent or attenuated}
- A61K 2039/523: {expressing foreign proteins}
- A61K 2039/543: {intranasal}
- A61K 2039/70: {Multivalent vaccine}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.

## Claims

### Claim 1

A transgenic Salmonella typhi Ty21a comprising a heterologous Shigella sonnei O-antigen biosynthetic gene region and a heterologous acid resistance biosynthetic gene system, said O-antigen biosynthetic gene region and said acid resistance biosynthetic gene system both being integrated into the Salmonella typhi Ty21a chromosome, wherein:
a. a heterologous Shigella sonnei O-antigen is stably expressed;
b. one or more heterologous Shigella acid resistance enzymes comprising a YbaS gene are stably expressed;
c. said transgenic Salmonella typhi Ty21a is more acid stable at pH 2.5 than Salmonella typhi Ty21a without the integrated acid resistance biosynthetic gene system;
d. an immune response is elicited against virulent Shigella sonnei challenge; and
e. an immune response is elicited against virulent Salmonella typhi challenge.

### Claim 2 (depends on 1)

The transgenic Ty21a of claim 1, wherein said heterologous Shigella sonnei O-antigen biosynthetic gene region comprises a wzz gene.

### Claim 3 (depends on 2)

The transgenic Ty21a of claim 2, wherein the wzz gene comprises (i) a DNA sequence that shares at least 90% sequence identity with the DNA sequence of nucleic acids 4,511,904 to 4,513,010 of SEQ ID NO: 4 or a complementary sequence thereof; (ii) the DNA sequence of nucleic acids 4,511,904 to 4,513,010 of SEQ ID NO: 4 or a complementary sequence thereof; or (iii) a DNA sequence that encodes a functional variant of the polypeptide encoded by the DNA sequence of nucleic acids 4,511,904 to 4,513,010 of SEQ ID NO: 4 or a complementary sequence thereof.

### Claim 4 (depends on 3)

The transgenic Ty21a of claim 3, wherein said heterologous Shigella sonnei O-antigen biosynthetic gene region comprises (i) a DNA sequence that shares at least 90% sequence identity with the DNA sequence of nucleic acids 4,500,076 to 4,513,461 of SEQ ID NO: 4 or a complementary sequence thereof; (ii) the DNA sequence of nucleic acids 4,500,076 to 4,513,461 of SEQ ID NO: 4 or a complementary sequence thereof; or (iii) a DNA sequence that encodes a functional variant of the polypeptide encoded by the DNA sequence of nucleic acids 4,500,076 to 4,513,461 of SEQ ID NO: 4 or a complementary sequence thereof.

### Claim 5 (depends on 4)

The transgenic Ty21a of claim 4, wherein the YbaS gene comprises (i) a DNA sequence that shares at least 90% sequence identity with the DNA sequence of nucleic acids 4,503,240 to 4,504,172 of SEQ ID NO: 1 or a complementary sequence thereof; (ii) the DNA sequence of nucleic acids 4,503,240 to 4,504,172 of SEQ ID NO: 1 or a complementary sequence thereof; or (iii) a DNA sequence that encodes a functional variant of the polypeptide encoded by the DNA sequence of nucleic acids 4,503,240 to 4,504,172 of SEQ ID NO: 1 or a complementary sequence thereof.

### Claim 6 (depends on 5)

The transgenic Ty21a of claim 5, additionally comprising an O-antigen biosynthetic gene region from a bacterial strain selected from the group consisting of: Shigella dysenteriae, Shigella flexneri, Shigella boydii, Escherichia coli, Salmonela enterica serovars, Vibrio cholera serotypes, Enterobacter species, Yersinia species, and Pseudomonas species.

### Claim 7 (depends on 6)

A composition comprising the transgenic Ty21a of claim 6 and a carrier.

### Claim 8 (depends on 7)

A vaccine comprising the composition of claim 7 which is suitable for oral administration.

### Claim 9 (depends on 8)

The vaccine of claim 8, wherein administration of said vaccine to a human population reduces the incidence of shigellosis in said human population subsequently exposed to pathogenic Shigella sonnei.

### Claim 10 (depends on 8)

The vaccine of claim 8, wherein administration of said vaccine to a human population reduces the incidence of typhoid fever in said human population subsequently exposed to pathogenic S. typhi.

### Claim 11 (depends on 8)

The vaccine of claim 8, wherein administration of said vaccine to a human population reduces the incidence of both shigellosis and typhoid fever in said human population subsequently exposed to both pathogenic Shigella sonnei and pathogenic S. typhi.

### Claim 12 (depends on 8)

A method of treating, preventing, or reducing the incidence of shigellosis in a human subject comprising orally administering the vaccine of claim 8.

### Claim 13 (depends on 8)

A method of treating, preventing, or reducing the incidence of typhoid fever in a human subject comprising orally administering the vaccine of claim 8.

### Claim 14 (depends on 8)

A method of treating, preventing, or reducing the incidence of both shigellosis and typhoid fever in a human subject comprising orally administering the vaccine of claim 8.

### Claim 15

(canceled)

### Claim 16

A transgenic Salmonella typhi Ty21a comprising a heterologous enterotoxogenic E. coli (ETEC) antigen biosynthetic gene region and a heterologous acid resistance biosynthetic gene system, wherein said ETEC antigen biosynthetic gene region and said acid resistance biosynthetic gene system are both integrated into the Salmonella typhi Ty21a chromosome, and wherein:
a. an ETEC antigen is stably expressed;
b. one or more heterologous Shigella acid resistance enzymes comprising a YbaS gene, are stably expressed;
c. said transgenic Salmonella typhi Ty21a is more acid stable at pH 2.5 than Salmonella typhi Ty21a without the integrated acid resistance biosynthetic gene system;
d. an immune response is elicited against virulent Enterotoxogenic E. coli challenge; and/or
e. an immune response is elicited against virulent Salmonella typhi challenge.

### Claim 17 (depends on 16)

The transgenic Ty21a of claim 16, wherein the YbaS gene comprises (i) a DNA sequence that shares at least 90% sequence identity with the DNA sequence of nucleic acids 4,503,240 to 4,504,172 of SEQ ID NO: 1 or a complementary sequence thereof; (ii) the DNA sequence of nucleic acids 4,503,240 to 4,504,172 of SEQ ID NO: 1 or a complementary sequence thereof; or (iii) a DNA sequence that encodes a functional variant of the polypeptide encoded by the DNA sequence of nucleic acids 4,503,240 to 4,504,172 of SEQ ID NO: 1 or a complementary sequence thereof.

### Claim 18 (depends on 17)

A composition comprising the transgenic Ty21a of claim 17 in combination with a carrier that renders said composition suitable for pharmaceutical use.

### Claim 19 (depends on 18)

A vaccine comprising the composition of claim 18, which is suitable for oral administration.

### Claim 20 (depends on 18)

A method of treating, preventing, or reducing the incidence of shigellosis or typhoid fever in a human subject comprising orally administering the composition of claim 18.

### Claim 21 (depends on 18)

A method of treating, preventing, or reducing the incidence of both shigellosis and typhoid fever in a human subject comprising orally administering the composition of claim 18.
